Hydrochloric Acid

Hydrochloric Acid

SCHEMBL234684

Cl.N=C(N)c1ccc(NC(=O)NCC(=O)NCc2cccc(Br)c2)cc1

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
F7 P08709 19/20 0.98
F10 P00742 3/20 0.98
F2 P00734 7/20 0.67
MTOR P42345 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL236558 0.99 F7 (1.00) F7F10F2MTOR
SCHEMBL4239365 0.89 F7 (0.82) F7F10F2MTOR
SCHEMBL4420144 0.86 F7 (1.00) F7F10F2
SCHEMBL13993085 0.83 F7 (0.72) F7F10F2MTOR
SCHEMBL13855059 0.82 F7 (0.70) F7F10F2MTOR
SCHEMBL4427050 0.80 F7 (1.00) F7F10F2
SCHEMBL4961414 0.80 F7 (0.67) F7F10F2MTOR
SCHEMBL5674444 0.76 F7 (0.64) F7F10F2
SCHEMBL4423265 0.76 F7 (1.00) F7F10F2
SCHEMBL13714617 0.75 F7 (0.65) F7F10F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656158-B1 LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITION OF FACTOR VII POLYPEPTIDES NOVO NORDISK HEALTHCARE AG (CH) 2016-03-09 EP disclosed
US-20130084274-A1 Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides NOVO NORDISK HEALTH CARE AG (CH) 2013-04-04 US disclosed
US-8318904-B2 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides NOVO NORDISK HEALTH CARE AG (CH) 2012-11-27 US disclosed
US-20120003206-A1 LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES NOVO NORDISK HEALTHCARE A/G (CH) 2012-01-05 US disclosed
US-8026214-B2 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides NOVO NORDISK HEALTH CARE AG (CH) 2011-09-27 US disclosed
US-7732405-B2 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides NOVO NORDISK HEALTH CARE AG (CH) 2010-06-08 US disclosed
US-20100056453-A1 Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides NOVO NORDISK HEALTHCARE A/G (CH) 2010-03-04 US disclosed
US-20060205648-A1 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides NOVO NORDISK HEALTHCARE A/G (CH) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205648-A1 Liquid, aqueous pharmaceutical compositions of factor VII polypeptides F7, F5, F12 F7 1/4885F10 16/4885F2 44/4885
US-20120003206-A1 LIQUID, AQUEOUS PHARMACEUTICAL COMPOSITIONS OF FACTOR VII POLYPEPTIDES F7, F5, F12 F7 1/4885F10 15/4885F2 40/4885
US-20100056453-A1 Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides F7, F5, F12 F7 1/4885F10 15/4885F2 40/4885
US-20130084274-A1 Liquid, Aqueous Pharmaceutical Compositions of Factor VII Polypeptides F7, F5, F12 F7 1/4885F10 15/4885F2 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.